Women of MIA lead the way in melanoma research at SMR
31 October 2018
The Society for Melanoma Research championed women from all sectors of melanoma research at its International Congress in Manchester. Unsurprisingly, Melanoma Institute Australia had a strong contingent of women presenting at SMR, including our Co-Medical Director Professor Georgina Long who, in a double world first, took over as the first female and first Australian President of SMR.
The Congress opened with a keynote presentation from Associate Professor Jennifer Wargo from MD Anderson Cancer Centre in Texas, who spoke on the benefits of teamwork and collaboration in advancing melanoma therapy. During the mid-morning plenary session, Professor Long presented exciting results from the KEYNOTE-029 1B study.
MIA PhD student Tuba Nur Gide presented some pioneering research regarding signatures of response and resistance in patients receiving immunotherapy. Looking at the genes expressed in melanoma samples from MIA patients, she found that genes involving immune memory and activation were higher in responders to immunotherapy, whereas non-responders showed higher levels of genes related to tumour adaptation and survival. While examining the immune cells in the tumours of responders, a specific type of T-cell, was found to be a good predictor of response and survival. The study is one of the first to investigate this in the combination therapy cohort.
Poster presentations from a host of MIA’s finest female minds were also on display throughout the Congress. Dr. Jenny Lee presented her research on the use of circulating tumour DNA (ctDNA) as a predictive marker of relapse and survival. She found that the pre-surgery levels of ctDNA, fragments of DNA from tumour cells that are floating in the bloodstream, could predict survival in Stage III melanoma patients undergoing complete lymph-node dissections.
MIA’s 2018 Medical Oncology Fellow Carina Owen presented on delayed-onset toxicity from anti-PD-1 therapy to highlight the need for clinicians to understand the long-term follow-up requirements of melanoma patients. MIA Biospecimen Bank Manager Valerie Jakrot’s poster presentation detailed the Bank’s role in sample collection, handling, storage and management of neo-adjuvant tissue and blood samples and the associated data.
Dr. Inês da Silva, a clinical researcher working in both medical oncology clinics and the laboratory with Prof Long, had two poster presentations at SMR. In an international collaboration, she developed a model to predict response rate, progression-free survival, overall survival and toxicity for patients on anti-PD-1-based therapies. This model could have a significant impact on clinical care after further study, as it only relied on patient information and a routine blood test. Her second poster presented significant data showing that melanoma patients who develop liver metastases are less responsive to combined immunotherapy with anti-PD-1 and anti-CTLA-4 immunotherapy. She found that liver metastases reduce the activity of the immune system, and recommends further study to possibly unlock these mechanisms and discover new drug targets for these patients.
A ‘STEM for Women' initiative, designed to empower women in melanoma research, was also launched at the SMR Congress. Featuring interviews with Professor Long, Associate Professor Wargo and Valerie Jakrot, among other trailblazing women, it aims to advise, support and inspire women in the scientific community.
In the final plenary session, Professor Georgina Long discussed challenge of resistance to melanoma therapies with a ‘call to action’ for all researchers in the field. Her presentation rounded out a Congress which illuminated and emphasised the ground breaking work of female leaders in the melanoma field.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.